Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Opinion & Analysis (NDAQ:MESO)

    Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

    Streetwise Reports May 14, 2020

    Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

    Streetwise Reports April 27, 2020

    Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

    Streetwise Reports April 16, 2020

    'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

    Streetwise Reports February 3, 2020

    Fiscal Year 'Reads Well' for Regenerative Medicine Company

    Streetwise Reports September 5, 2019

    Australian Regenerative Medicine Firm 'Lands a Great Partner in China'

    Streetwise Reports July 23, 2018

    Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

    Streetwise Reports April 25, 2018

    Mesoblast heart failure trial delivers positive interim results

    The Life Sciences Report May 4, 2017

    The ASX: investing in an emerging biotech frontier

    The Life Sciences Report August 10, 2016